Loading clinical trials...

COMPLETEDPhase 3NCT01626456

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.

Lead sponsor: Alkermes, Inc.•25 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 3

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

NCT07565428 · Negative Symptoms of Schizophrenia

RECRUITINGNA

FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis

NCT07645443 · Early Onset Psychosis, First Psychotic Episode Within the Last 5 Years, and more

RECRUITINGNA

Deep Brain Stimulation for Psychosis

NCT06257056 · Treatment-Refractory Schizophrenia

RECRUITINGPhase 2

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

NCT07288333 · Schizophrenia

RECRUITINGPhase 3

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

NCT07105098 · Schizophrenia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 25, 2018Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment478

Start dateJun 2012

Last updatedSep 25, 2018

Condition

Schizophrenia

Locations shown

Alkermes Investigational Site

Little Rock, Arkansas

Alkermes Investigational Site

Little Rock, Arkansas

Alkermes Investigational Site

Springdale, Arkansas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 25, 2018Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis

Deep Brain Stimulation for Psychosis

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Trial snapshot

Condition

Locations shown

For caregivers